Description
This executive-level report provides a strategic snapshot of healthcare systems and reimbursement pathways for molecular diagnostics across France, Germany, Italy, and Spain. It highlights critical differences in HTA processes, stakeholder roles, coding structures, and access schemes (e.g., RIHN, NUB, LEA, CGen), offering manufacturers a clear roadmap to plan early and effectively.
Designed for diagnostics developers, market access professionals, and investors, the report includes cancer burden statistics, EU funding initiatives, and practical recommendations for navigating decentralized healthcare systems in Europe.
